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Background and aim: Enteric fistulas are defined by their sites of origin, communication and
flow. We evaluate the treatment of complex patients with entero-cutaneous fistulae with
large abdominal wall defects.
Materials and methods: Retrospective case note review of 19 patients (15males,median age 46
years) treated at the Department of Surgical Sciences, University of Insubria, Varese, Italy.
Theseweredistinguishedbymultiple/wide gastrointestinal fistulaorifices,with total discon-
tinuity of bowel. Fistulas were not covered by abdominal wall thus presenting with a giant
abdominal wall defects. Surgery was planned once adequate nutritional status was present.
Results: All fistulas resulted fromprevious surgery for IBD in 7 cases (37%), abdominal trauma
4 (21%), acutenecrotic infected pancreatitis 3 (16%), intra-abdominalmalignancy 3 (16%), and
diverticular disease 2 (10%). Themost common site of presentationwas ileum (80%). Median
fistula output was 800 ml/day (range 400–1600 ml/day). Seltzer’s prognostic index identified
malnutrition in 70% of patients at the time of presentation. The elapsed mean time from
onset of fistula and elective time of surgical management were 184 days (range 20–2190
days). The VAC system was used in the last 7 patients preoperatively and in 6 patients with
postoperative abdominal wound dehiscences that could not be closed immediately and
who were at high risk for healing complications. There were no complications from the
VAC therapy. Surgery was successful in 69% of cases. Mortality rate was 21%. Factors related
to mortality were persistent malignancy, malnutrition and sepsis.
Conclusions: After optimization of nutritional status surgery with en bloc resection of fistula
offers best results. In this series, cancer and sepsis were unfavourable factors for outcome.
These fistulas may be successfully managed with a multidisciplinary approach.
ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction the intestine (entero-enteral) or the skin (entero-cutaneous).1Gastrointestinal (GI) fistula is an abnormal leaks of the bowel
contents to other organs (i.e. colovesical fistula), other parts of; fax: þ390332260260.
subria.it (G. Dionigi).
al Associates Ltd. PublishThe majority of fistulas are consequences of a surgical proce-
dure. Causes include disruption of the anastomotic suture
line, unintentional enterotomy or inadvertent bowel injuryed by Elsevier Ltd. All rights reserved.
Fig. 1 – A case of multiple and wide entero-cutaneous
fistulas with total discontinuity of bowel ends (‘‘end
fistulae’’), associated with a large dehisced abdominal
wound.
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sults of trauma. Inflammatory processes, such as inflamma-
tory bowel disease (IBD), may also cause fistulas.2
By convention, GI fistulas are usually defined by their sites
of origin, communication and flow 3; moreover, complex fis-
tula are associated with an intra-abdominal abscess cavity.4
Severe malnutrition and fluid, electrolyte or metabolic dis-
turbances are themain effect of GI fistulas depending on their
location along the intestine.5–7 Furthermore, they may also be
a source of skin problems.8
Recent evidences support the fact that fistula output is
a significant factor influencing closure of GI fistula, with the
odds of spontaneous closure 3 times greater for low output fis-
tulas (effluent< 200 ml/24 h) than for high output fistulas
(effluent> 200 ml/24 h).9,10 Despite advances in metabolic
and nutritional care, mortality rates remain high.11
This paper reviews our experience on the treatment of
entero-cutaneous fistula to evaluate current management
practice and outcome. Because GI fistulas display so much
variability from patient to patient (high versus low output,
site of origin, presence or absence of associated organ dys-
function, and malnutrition), we evaluate the treatment of
a specific group of patientswith high output entero-cutaneous
fistulae associated with a large dehiscence of the abdominal
wound.2. Materials and methods
A retrospective descriptive study of 19 patients (15 males, 4
females; median age 46 years, range 21–79) with entero-
cutaneous fistulas associatedwith a large dehisced abdominal
wound treated at a single institution from 2000 to May 2007.
This is the Department of Surgical Sciences, University of
Insubria, in Varese (Italy) which is a university hospital and
referral centre.
At examination all patients presented with grossly visible
intestinal mucosa; in details, these were distinguished by
multiple and wide fistula orifices (more than 1 cm in diame-
ter), and complete anastomotic disruption with total disconti-
nuity of bowel ends (‘‘end fistulae’’) (Fig. 1). All these fistulas
presented with an effluent >200 ml/24 h and the orifices of
the fistulas were not covered by abdominal wall, thus present-
ing with a large abdominal wall defect.
Upper gastrointestinal tract (esophagus and stomach), bil-
iary and pancreatic fistulas were excluded from this study.12
Outside referrals accounted for all patients. Patients were fol-
lowed-up for a median of 22 months (range 1–131 months)
after definitive surgical treatment.
Patients were managed by a multidisciplinary team. A
daily record was kept of fistula, urine, stomal and/or faecal
output.
Sources of sepsis were identified and treated quickly, using
appropriate radiological investigation and culture of all sites
of potential infection. All patients had more than one investi-
gation; small bowel contrast follow-through studies were
most commonly used, followed by fistulography and retro-
grade studies of the distal bowel. Suspected collections were
investigated using computer tomography (CT) or ultrasonog-
raphy (US).13We used the Seltzer instant prognostic index to identify
nutritional status.14 All patients were supported with artificial
alimentation as total parental nutrition (TPN) or total enteral
nutrition (TEN). We consider adequate indexes of good nutri-
tional status serum albumin level3.5 g/dl and blood lympho-
cytic count cells 1500/mm3.
We define the following clinical events: T1 the time of first
laparotomy; T2 onset/first recognition of fistula; and T3
the elective time of definitive surgical treatment of entero-
cutaneous fistula.
Skin protection was achieved at an early stage using a vari-
ety of barriers, adhesives and wound drainage bags (Bogota
bag),15,16 allowing containment, drainage, continuous irriga-
tion of the wound with saline, and measurement of effluent
and to facilitate healing.
The vacuum assisted closure (VAC) system (Kinetic Con-
cepts, Inc., San Antonio, TX, USA) was used preoperatively
and postoperatively in patients with an abdominal wound
that could not be closed immediately and who were at high
risk for healing complications. The VAC device was main-
tained on a continuous mode with a negative pressure from
75 to 125 mmHg (Fig. 2). The dressing was changed every
2 days. In most cases, protection of skin was directed by the
surgeon and ostomy nurses.
Initial treatment was conservative except for patients with
an abscess who needed urgent drainage. Subcutaneous or intra-
venous injectionoctreotidewasused in4patients preoperatively
in an attempt to decrease fistula output.17 In nonepatients
octreotide was administered as prophylaxis postoperatively.
Surgery was planned once adequate nutritional status was
achieved. Surgical procedure comprised re-laparotomy, en
bloc resection of the involved bowel and overlying skin
(Fig. 3a, b), and anastomosis. Careful hand-sewn 2-layered
lateral-to-lateral anastomosis created to ensure goodmucosal
apposition and serosal closure. Finally we ensured that the
entire intestine have been mobilized and free from injury.
The bowel was temporary defunctioned at fistula surgery by
Fig. 2 – Skin treatment with VAC system in a case of
entero-cutaneous fistulas associated with a large dehisced
abdominal wound.
Fig. 3 – (a, b) Laparotomy with en bloc resection of the
involved bowel and overlying skin.
Table 1 – Site of entero-cutaneous fistula (N[ 19)
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in those patients presenting with complex GI fistulas with
multiple intra-abdominal abscess and entero-enteral fistulas,
in patients requiring more than one bowel anastomoses.
Before closing the abdomen,we considered placing a trans-
gastric jejunostomy for early postoperative enteral feeding.
We placed soft, closed-suction drains only for abscess cavities
discovered intraoperatively, with removal following a CT scan
or US that demonstrated obliteration of the space. During ab-
dominal closure, omentum was placed between the anasto-
mosis and the midline wound, if possible.
We have developed a staged approach for abdominal wall
reconstruction: plastic closure with flaps was preferable to
prosthetic mesh in an effort to minimize the incidence of
postoperative fistula caused by foreign material. VAC therapy
continued until the integrity of the abdominal wall was re-
established by surgical procedures or secondary healing with
delayed primary wound closure.
All procedures were performed by one senior surgeon (RD).3. Results
Fistulae distribution is reported in Table 1. Fifteen (79%) fistu-
las were complex: fistula involved multiple bowel loops with
an intra-abdominal chronic abscess cavity and internal fistu-
las. All fistulas (100%) resulted frompreviously abdominal sur-
gery due to inadvertent enterotomies (unrecognized bowel
injuries) or anastomotic dehiscences; in details these had
IBD (Crohn’s) in 7 cases (37%), previous surgery for abdominal
trauma 4 (21%), acute necrotic infected pancreatitis 3 (16%),
intra-abdominal malignancy (2 colorectal cancer, 1 gyneco-
logic tumor) 3 (16%), and diverticular disease 2 (10%) (Table
2). These operations consisted also in lysis of adhesions in 8/
19 of cases (42%). Mean number of previous laparotomies
was 4 (range 2–7). Median fistula output was 800 ml/day (range
400–1600 ml/day).Table 2 – Postoperative surgical cause of entero-







Table 3 – Trend of nutritional index (according to Seltzer’s
nutritional prognostic index) and clinical evolution. Scale
from low to high represents nutritional index
T2: first recognition of fistula; and T3: time of definitive surgical
treatment. Patients (PT) 11, 15, and 17 had recurrence of a high out-
put fistula (PT15 died). PTs 6, 12, and 16 died (all from previous sur-
gery for malignancy). Five sixth of these patients had medium to
low nutritional index in T3.
Fig. 4 – Stable cutaneous coverage by skin grafting.
i n t e r n a t i o n a l j o u r n a l o f s u r g e r y 6 ( 2 0 0 8 ) 5 1 – 5 654The elapsedmean time from T1 to T2 was 54 days (range 3–
485). The elapsedmean time from onset (T2) and elective time
(T3) of surgical management were 184 days (range 20–2190
days).
Themajority of the patientsweremalnourished at the time
of presentation (T2). Seltzer’s prognostic index identified mal-
nutrition in majority of patients (70%) at the time of presenta-
tion (T2). Serum albumin and lymphocytic count showed
higher levels at the end of treatment (T3) than at the beginning
(T2). In particular, the mean serum albumin and blood lym-
phocytic count cells were 3.32 g/dl, 1350 cells/mm3 and
3.45 g/dl, 1560 cells/mm3, respectively, at T2 and T3 (Table 3).
Between T2 and T3, 13 patients (69%) were supported with
artificial alimentation (TPN 70% and TEN 30%).
No spontaneous closure/healing of fistulae was observed.
In 4 patients, the effect of octreotide was monitored; in none
patients, octreotide was of benefit in output reduction or
spontaneous resolution.
Six patients (31%) underwent radiologically CT-guided
drainage procedures for abscess cavities before definitive sur-
gery as part of initial resuscitation.
Definitive surgery was successful in 13 (69%) cases. The
bowel was defunctioned at fistula surgery in 6 patients
(31.5%) by fashioning a small bowel stoma proximal to the
anastomoses (end/loop ileostomy). There were no intraopera-
tive complications. Three patients underwent radiologically
CT-guided drainage procedures for abscess cavities after de-
finitive surgery (16%). Postoperative catheter-related sepsis
occurred in 7 patients (36%). Metabolic complications were
common, and included hypoalbuminaemia (78%), hypocal-
caemia (73%), anemia (63%), and deranged liver function
(63%).
The VAC system was used in the last 7 patients preopera-
tively and in 6 patients with postoperative abdominal wound
dehiscences that could not be closed immediately and who
were at high risk for healing complications. There were nocomplications from the VAC therapy. Stable cutaneous cover-
age was subsequently achieved in all patients by mesh graft-
ing (13) (Fig. 4), or secondary intention healing (6). No
patients had part of their VAC therapy as outpatients.
Six patients (31.5%) developed recurrence. Of these 6 cases
3 had low output <200 ml/24 h fistulas all recovering conser-
vatively with spontaneous closure. Three patients with high
output re-fistulation required new surgery.
No patient died during the course of treatment for their in-
testinal fistulas (between T2 and T3). The overall in-hospital
mortality rate after definitive surgery was 21% (4/19). Two pa-
tients developed a disseminated intravascular coagulopathy
secondary to sepsis, and died from multiple organ dysfunc-
tion. Two patients died from cardiorespiratory arrest. Three
fourth of these patients were affected by fistulas resulted
from surgery for intra-abdominal malignancy (persistent/
recurrence of cancer).4. Discussion
This paper is a descriptive, retrospective report of a small
number but complex patients with high output entero-
cutaneous fistulas associatedwith a large dehisced abdominal
wound. This condition is a challenging clinical problem.
GI fistulas are associatedwith prolonged hospital stay, high
morbidity and mortality.11 In this study group in which fistula
orifices were not covered by the abdominal wall no spontane-
ous closure/healing was observed. The length of the fistula
tract is important because greater the distance between the
bowel and the skin, higher the incidence of spontaneous clo-
sure.18,19 A longer tract not only decreases the likelihood of
skin epithelialization but also provides a greater resistance to
flow through the tract, promoting closure.18,19 Furthermore,
the exposed bowel is at risk for further fistula formation in un-
protected loops because of desiccation, dressing changes and
lacerations. Moreover, drainage from entero-cutaneous fistu-
lae is associated with severe inflammatory skin reactions
such asmaceration and erythema. In our experience, success-
ful and simple techniques of external control of the fistula in-
cluded ‘‘laparostoma’’ and the VAC system.20,21 These
devices allow quantification and characterization of the
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rigation, prevent desiccation of exposed loops of bowel, sim-
plify subsequent fluid and electrolyte management.20,21
Negative pressure wound therapy has been employed as
a treatment strategy for patients with complex GI fistula in
the preoperative and postoperative definitive surgery (‘‘VAC
staged therapy’’). There were no complications associated
with VAC in the patient population.
Recent improvements in term of reduced mortality associ-
ated to entero-cutaneous fistula have resulted from a combi-
nation of factors, including advances in critical care,
imaging techniques, nutritional support and antimicrobial
therapy.11,22 A complete multidisciplinary approach is recom-
mended consisting of surgeons, microbiologists, physiothera-
pist, stomatherapist, radiologist nurses and dietitians.
Defining the anatomy of a fistula is also essential for future
operative planning. US and multiple CT scans are required
to ensure optimal drainage of septic foci as abscess cavities.
In our experience imaging was helpful to determine anatomy
of fistula, as fistulography defines tract, small bowel or barium
enema defines state of intestine or distal obstruction.23,24
Radiological studies as well as interventional radiology were
increasingly employed over the duration of this study.
Recent prospective studies have failed to demonstrate
a benefit in closure rate or outcome and question whether so-
matostatin produces a meaningful reduction in fistula out-
put.25,26 Because of the complex nature of these particular
cases, somatostatin and its analogues were considered but
occasionally used in this study.
The timing of a major GI reconstruction procedure is a key
point. The decision to proceed with definitive surgical recon-
struction should be carried out onlywhen the patient is stable,
nutritional replete, apyrexial, and if the fistula effluent shows
no signs of decreasing in volume after 4–6weeks of nutritional
support, usually after at least 3–6 months, and an appropriate
plan has been developed.3,4,7,27
Given the rarity of these complex high output entero-
cutaneous fistulas in general not covered by abdominal wall
in particular, it is virtually impossible to set up a controlled
prospective trail large enough to yield unbiased results for dif-
ferent types of treatment. Moreover, for the small number of
cases it is not a possible statistical analysis and comparison
between the successful and failed cases. However, malnutri-
tion is an unfavourable prognostic factor (Table 3). At present,
treatment choices are based on clinical situation and do not
have a specific algorithm.
Surgical management with bowel resection, including the
fistula, is a preferred method of treatment.28 Multivariate
analysis has demonstrated that recurrence ismore likely after
oversewing than after resection.29
Early surgery is only instituted for complications such as ob-
struction, peritonitis or abscess formation.3,4 The delayed ap-
proach has several advantages: the potential blood loss from
freshadhesions is reducedand the chance of a secondbowel in-
jurydecreasedbecausecleareranatomicdefinitionofstructures
within the abdomen is possible. In this study the mean delay
fromfistula recognition to operative repair inwas 26weeks. Re-
sectionof the leaking segmentof bowelwith carefulhand-sewn
2-layered lateral-to-lateral anastomosis has the best chance of
resolvingthefistulaacutely.Theanastomosismaybereinforcedby greater omentum, if possible. Meticulous technique can cer-
tainly lessen the risk of postoperative fistula reformation.
Most other large series publish overall mortalities around
5–15% notably the Cleveland Clinics and St Mark’s series.28,29
In this study mortality was all postoperative and quoted at
21%; in fact these are a selected group of complex patients
with grossly visible intestinal mucosa, distinguished bymulti-
ple and wide fistula orifices, with total discontinuity of bowel
ends, effluent >200 ml/24 h and presenting with a large ab-
dominal wall defect. Moreover, 79% of these fistulas involved
multiple bowel loopswith an intra-abdominal chronic abscess
cavity and internal fistulas.
A higher mortality and recurrence fistula rate were ob-
served in patients previously treated for malignant disease.
In one report, uncontrollable sepsis was associatedwith death
in up to 85% of patients, many of whomhad underlyingmalig-
nancy (50%).22 The decision to operate on patients withmalig-
nant fistulas is therefore often unclear. Factors to consider
include the patient’s life expectancy, the presumed extent of
resection, prior administration of radiation and chemother-
apy, persistent malignancy and the definition of fistula (radio-





Written consent of the patients was obtained for publication
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